# Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study

> **NCT03545035** · — · COMPLETED · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 104 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** idelalisib and rituximab

## Key facts

- **NCT ID:** NCT03545035
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-06
- **Primary completion:** 2020-10-28
- **Final completion:** 2020-10-28
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2022-05-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03545035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03545035, "Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03545035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*